ARTRYA Ltd Cash Flow Conversion Efficiency
ARTRYA Ltd cash flow conversion efficiency. Based on the latest financial reports, ARTRYA Ltd (AYA) has a cash flow conversion efficiency ratio of -0.122x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-10.88 Million ≈ $-7.70 Million USD) by net assets (AU$89.35 Million ≈ $63.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ARTRYA Ltd (2019–2025)
Cash flow conversion efficiency of ARTRYA Ltd from 2019 to 2025. This chart illustrates how ARTRYA Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AYA stock price and chart for real-time trading data and today's change.
ARTRYA Ltd Cash Flow Conversion Ratio Explained
ARTRYA Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ARTRYA Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ARTRYA Ltd ranked by their cash flow conversion efficiency. Also see AYA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Sanfo Outdoor Products Co Ltd
SHE:002780
|
-0.026x |
|
Camping World Holdings Inc
NYSE:CWH
|
0.290x |
|
Marcopolo S.A
SA:POMO3
|
0.205x |
|
Altshuler Shaham Financial LTD
TA:ALTF
|
0.027x |
|
Rongfeng Holding Group
SHE:000668
|
-0.065x |
|
Chengdu Dahongli Machinery Co Ltd
SHE:300865
|
0.015x |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
0.088x |
|
Beijing InHand Networks Technology Co Ltd
SHG:688080
|
0.071x |
Annual Cash Flow Conversion Efficiency for ARTRYA Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of ARTRYA Ltd from 2019 to 2025. Review financial agility of ARTRYA Ltd to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$21.29 Million ≈ $15.06 Million |
AU$-14.27 Million ≈ $-10.10 Million |
-0.670x | +26.89% |
| 2024-06-30 | AU$16.80 Million ≈ $11.89 Million |
AU$-15.41 Million ≈ $-10.90 Million |
-0.917x | -160.90% |
| 2023-06-30 | AU$30.56 Million ≈ $21.62 Million |
AU$-10.74 Million ≈ $-7.60 Million |
-0.351x | -48.68% |
| 2022-06-30 | AU$40.64 Million ≈ $28.76 Million |
AU$-9.61 Million ≈ $-6.80 Million |
-0.236x | -711.62% |
| 2021-06-30 | AU$51.05 Million ≈ $36.12 Million |
AU$-1.49 Million ≈ $-1.05 Million |
-0.029x | +95.53% |
| 2020-06-30 | AU$2.49 Million ≈ $1.76 Million |
AU$-1.62 Million ≈ $-1.15 Million |
-0.651x | -478.82% |
| 2019-06-30 | AU$852.97K ≈ $603.53K |
AU$-95.94K ≈ $-67.89K |
-0.112x | -- |
About ARTRYA Ltd
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a suite ifcloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography sca… Read more